請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69694
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 賴亮全(Liang-Chuan Lai) | |
dc.contributor.author | Ming-Zhen Chen | en |
dc.contributor.author | 陳姳蓁 | zh_TW |
dc.date.accessioned | 2021-06-17T03:24:07Z | - |
dc.date.available | 2020-08-27 | |
dc.date.copyright | 2020-08-27 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-18 | |
dc.identifier.citation | 1. L. A. Torre, R. L. Siegel, and A. Jemal. (2016). Lung cancer statistics, Lung cancer and personalized medicine. Springer, p. 1.
2. F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin, 68:394. 3. W. D. Travis. (2002). Pathology of lung cancer. Clinics in chest medicine, 23:65. 4. J. R. Molina, P. Yang, S. D. Cassivi, S. E. Schild, and A. A. Adjei. (2008). Non–Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clin Prov. 5. W. D. Travis, E. Brambilla, A. P. Burke, A. Marx, and A. G. J. J. o. T. O. Nicholson. (2015). Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol, 10:1240. 6. W. D. Travis, E. Brambilla, A. G. Nicholson, Y. Yatabe, J. H. Austin, M. B. Beasley, L. R. Chirieac, S. Dacic, E. Duhig, and D. B. J. J. o. t. o. Flieder. (2015). The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol, 10:1243. 7. J. S. Chang, L.-T. Chen, Y.-S. Shan, S.-F. Lin, S.-Y. Hsiao, C.-R. Tsai, S.-J. Yu, and H.-J. J. M. Tsai. (2015). Comprehensive analysis of the incidence and survival patterns of lung cancer by histologies, including rare subtypes, in the era of molecular medicine and targeted therapy: A nation-wide cancer registry-based study from Taiwan. Medicine, 94. 8. D. S. Ettinger, W. Akerley, G. Bepler, M. G. Blum, A. Chang, R. T. Cheney, L. R. Chirieac, T. A. D'Amico, T. L. Demmy, and A. K. P. J. J. o. t. n. c. c. n. Ganti. (2010). The role of thoracoscopic pneumonectomy in the management of non-small cell lung cancer: A multicenter study. J Thorac Cardiovasc Surg, 8:740. 9. J. Fraumeni. (1975). Respiratory carcinogenesis: an epidemiologic appraisal. J Natl Cancer Inst, 55:1039. 10. D. Janerich, W. Thompson, and L. Varela. (1990). Lung cancer and exposure to tobacco smoke in the household. N Engl J Med, 323:632. 11. D. Trichopoulos, A. Kalandidi, L. Sparros, and B. Macmahon. (1981). Lung cancer and passive smoking. Int J Cancer, 27:1. 12. R. Doll, and R. Peto. (1976). Mortality in relation to smoking: 20 years' observations on male British doctors. Br med J, 2:1525. 13. C.-K. Toh, F. Gao, W.-T. Lim, S.-S. Leong, K.-W. Fong, S.-P. Yap, A. A. Hsu, P. Eng, H.-N. Koong, and A. Thirugnanam. (2006). Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol, 24:2245. 14. J. Rachtan. (2002). Smoking, passive smoking and lung cancer cell types among women in Poland. Lung Cancer, 35:129. 15. S. A. Khuder. (2001). Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer, 31:139. 16. M. Kreuzer, L. Kreienbrock, K. M. Müller, M. Gerken, and E. Wichmann. (1999). Histologic types of lung carcinoma and age at onset. Cancer, 85:1958. 17. R. C. Brownson, M. C. Alavanja, N. Caporaso, E. J. Simoes, and J. C. Chang. (1998). Epidemiology and prevention of lung cancer in nonsmokers. Epidemiol Rev, 20:218. 18. T. Hirayasu, T. Iwamasa, Y. Kamada, Y. Koyanagi, H. Usuda, and K. Genka. (1996). Human papillomavirus DNA in squamous cell carcinoma of the lung. J Clin Pathol, 49:810. 19. L. P. Ger, S. H. Liou, C. Y. Shen, S. J. Kao, and K. T. Chen. (1992). Risk factors of lung cancer. J Formos Med Assoc, 91 Suppl 3:S222. 20. H. Yamamoto, H. Shigematsu, M. Nomura, W. W. Lockwood, M. Sato, N. Okumura, J. Soh, M. Suzuki, Wistuba, II, K. M. Fong, H. Lee, S. Toyooka, H. Date, W. L. Lam, J. D. Minna, and A. F. Gazdar. (2008). PIK3CA mutations and copy number gains in human lung cancers. Cancer Res, 68:6913. 21. D. A. Eberhard, B. E. Johnson, L. C. Amler, A. D. Goddard, S. L. Heldens, R. S. Herbst, W. L. Ince, P. A. Jänne, T. Januario, D. H. Johnson, P. Klein, V. A. Miller, M. A. Ostland, D. A. Ramies, D. Sebisanovic, J. A. Stinson, Y. R. Zhang, S. Seshagiri, and K. J. Hillan. (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol, 23:5900. 22. H. Shigematsu, L. Lin, T. Takahashi, M. Nomura, M. Suzuki, Wistuba, II, K. M. Fong, H. Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Z. Feng, J. A. Roth, J. Herz, J. D. Minna, and A. F. Gazdar. (2005). Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 97:339. 23. S. Toyooka, T. Tsuda, and A. F. Gazdar. (2003). The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat, 21:229. 24. P. Hainaut, and G. P. Pfeifer. (2001). Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis, 22:367. 25. T. P. Lu, M. H. Tsai, J. M. Lee, C. P. Hsu, P. C. Chen, C. W. Lin, J. Y. Shih, P. C. Yang, C. K. Hsiao, L. C. Lai, and E. Y. Chuang. (2010). Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women. Cancer Epidemiol Biomarkers Prev, 19:2590. 26. P. H. Ko, G. Lenka, Y. A. Chen, E. Y. Chuang, M. H. Tsai, Y. P. Sher, and L. C. Lai. (2020). Semaphorin 5A suppresses the proliferation and migration of lung adenocarcinoma cells. Int J Oncol, 56:165. 27. (1999). Unified nomenclature for the semaphorins/collapsins. Semaphorin Nomenclature Committee. Cell, 97:551. 28. E. Gherardi, C. A. Love, R. M. Esnouf, and E. Y. Jones. (2004). The sema domain. Curr Opin Struct Biol, 14:669. 29. P. K. Hota, and M. Buck. (2012). Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions. Cell Mol Life Sci, 69:3765. 30. L. T. Alto, and J. R. Terman. (2017). Semaphorins and their Signaling Mechanisms. Methods Mol Biol, 1493:1. 31. C. Christensen, N. Ambartsumian, G. Gilestro, B. Thomsen, P. Comoglio, L. Tamagnone, P. Guldberg, and E. Lukanidin. (2005). Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis. Cancer Res, 65:6167. 32. M. Hattori, M. Osterfield, and J. G. Flanagan. (2000). Regulated cleavage of a contact-mediated axon repellent. Science, 289:1360. 33. C. Esselens, J. Malapeira, N. Colomé, C. Casal, J. C. Rodríguez-Manzaneque, F. Canals, and J. Arribas. (2010). The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration. J Biol Chem, 285:2463. 34. K. Browne, W. Wang, R. Q. Liu, M. Piva, and T. P. O'Connor. (2012). Transmembrane semaphorin5B is proteolytically processed into a repulsive neural guidance cue. J Neurochem, 123:135. 35. R. J. Pasterkamp, and R. J. Giger. (2009). Semaphorin function in neural plasticity and disease. Curr Opin Neurobiol, 19:263. 36. S. Delaire, A. Elhabazi, A. Bensussan, and L. Boumsell. (1998). CD100 is a leukocyte semaphorin. Cell Mol Life Sci, 54:1265. 37. C. Bougeret, I. G. Mansur, H. Dastot, M. Schmid, G. Mahouy, A. Bensussan, and L. Boumsell. (1992). Increased surface expression of a newly identified 150-kDa dimer early after human T lymphocyte activation. J Immunol, 148:318. 38. A. D. Gitler, M. M. Lu, and J. A. Epstein. (2004). PlexinD1 and semaphorin signaling are required in endothelial cells for cardiovascular development. Dev Cell, 7:107. 39. M. Hayashi, T. Nakashima, M. Taniguchi, T. Kodama, A. Kumanogoh, and H. Takayanagi. (2012). Osteoprotection by semaphorin 3A. Nature, 485:69. 40. J. Roche, F. Boldog, M. Robinson, L. Robinson, M. Varella-Garcia, M. Swanton, B. Waggoner, R. Fishel, W. Franklin, R. Gemmill, and H. Drabkin. (1996). Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene, 12:1289. 41. J. R. Basile, R. M. Castilho, V. P. Williams, and J. S. Gutkind. (2006). Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. Pnas, 103:9017. 42. Y. Tomizawa, Y. Sekido, M. Kondo, B. Gao, J. Yokota, J. Roche, H. Drabkin, M. I. Lerman, A. F. Gazdar, and J. D. Minna. (2001). Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21. 3 candidate tumor suppressor gene SEMA3B. Pnas, 98:13954. 43. X. Li, and A. Y. Lee. (2010). Semaphorin 5A and plexin-B3 inhibit human glioma cell motility through RhoGDIalpha-mediated inactivation of Rac1 GTPase. J Biol Chem, 285:32436. 44. A. Sadanandam, S. S. Sidhu, S. Wullschleger, S. Singh, M. L. Varney, C. S. Yang, A. E. Ashour, S. K. Batra, and R. K. Singh. (2012). Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation. Br J Cancer, 107:501. 45. S. Saxena, A. Purohit, M. L. Varney, Y. Hayashi, and R. K. Singh. (2018). Semaphorin-5A maintains epithelial phenotype of malignant pancreatic cancer cells. Bbc Cancer, 18:1283. 46. C. Y. Shen, Y. C. Chang, L. H. Chen, W. C. Lin, Y. H. Lee, S. T. Yeh, H. K. Chen, W. Fang, C. P. Hsu, J. M. Lee, T. P. Lu, P. W. Hsiao, L. C. Lai, M. H. Tsai, and E. Y. Chuang. (2018). The extracellular SEMA domain attenuates intracellular apoptotic signaling of semaphorin 6A in lung cancer cells. Oncogenesis, 7:95. 47. S. M. Bahri, W. Chia, and X. Yang. (2001). Characterization and mutant analysis of the Drosophila sema 5c gene. Dev Dyn, 221:322. 48. R. H. Adams, H. Betz, and A. W. Püschel. (1996). A novel class of murine semaphorins with homology to thrombospondin is differentially expressed during early embryogenesis. Mech Dev, 57:33. 49. Y. Verhoeven, S. Tilborghs, J. Jacobs, J. De Waele, D. Quatannens, C. Deben, H. Prenen, P. Pauwels, X. B. Trinh, A. Wouters, E. L. J. Smits, F. Lardon, and P. A. van Dam. (2020). The potential and controversy of targeting STAT family members in cancer. Semin Cancer Biol, 60:41. 50. M. J. Wilderman, J. Sun, A. S. Jassar, V. Kapoor, M. Khan, A. Vachani, E. Suzuki, P. A. Kinniry, D. H. Sterman, L. R. Kaiser, and S. M. Albelda. (2005). Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung. Cancer Res, 65:8379. 51. K. Fink, and N. Grandvaux. (2013). STAT2 and IRF9: Beyond ISGF3. Jakstat, 2:e27521. 52. L. Yoo, A. R. Yoon, C.-O. Yun, and K. C. Chung. (2018). Covalent ISG15 conjugation to CHIP promotes its ubiquitin E3 ligase activity and inhibits lung cancer cell growth in response to type I interferon. Cell Death Dis, 9:97. 53. J. F. Zhang, Y. Chen, G. S. Lin, J. D. Zhang, W. L. Tang, J. H. Huang, J. S. Chen, X. F. Wang, and Z. X. Lin. (2016). High IFIT1 expression predicts improved clinical outcome, and IFIT1 along with MGMT more accurately predicts prognosis in newly diagnosed glioblastoma. Hum Pathol, 52:136. 54. K. Ghoreschi, A. Laurence, and J. J. O'Shea. (2009). Janus kinases in immune cell signaling. Immunol Rev, 228:273. 55. V. Cheriyath, J. Kaur, A. Davenport, A. Khalel, N. Chowdhury, and L. Gaddipati. (2018). G1P3 (IFI6), a mitochondrial localised antiapoptotic protein, promotes metastatic potential of breast cancer cells through mtROS. Br. J. Cancer, 119:52. 56. N. L. Prigozhina, L. Zhong, E. A. Hunter, I. Mikić, S. Callaway, D. R. Roop, M. A. Mancini, D. A. Zacharias, J. H. Price, and P. M. McDonough. (2007). Plasma membrane assays and three-compartment image cytometry for high content screening. Assay Drug Dev Technol, 5:29. 57. C. Tristan, N. Shahani, T. W. Sedlak, and A. Sawa. (2011). The diverse functions of GAPDH: Views from different subcellular compartments. Cell Signal, 23:317. 58. J. Chen, J. Zhao, L. Chen, N. Dong, Z. Ying, Z. Cai, D. Ji, Y. Zhang, L. Dong, Y. Li, L. Jiang, M. J. Holtzman, and C. Chen. (2015). STAT1 modification improves therapeutic effects of interferons on lung cancer cells. J Transl Med, 13:293. 59. K. E. Luker, C. M. Pica, R. D. Schreiber, and D. Piwnica-Worms. (2001). Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. Cancer Res, 61:6540. 60. C. Park, S. Li, E. Cha, and C. Schindler. (2000). Immune response in Stat2 knockout mice. Immunity, 13:795. 61. M. Gao, Y. Lin, X. Liu, Y. Li, C. Zhang, Z. Wang, Z. Wang, Y. Wang, and Z. Guo. (2019). ISG20 promotes local tumor immunity and contributes to poor survival in human glioma. OncoImmunology, 8:e1534038. 62. B. N. Bidwell, C. Y. Slaney, N. P. Withana, S. Forster, Y. Cao, S. Loi, D. Andrews, T. Mikeska, N. E. Mangan, S. A. Samarajiwa, N. A. de Weerd, J. Gould, P. Argani, A. Möller, M. J. Smyth, R. L. Anderson, P. J. Hertzog, and B. S. Parker. (2012). Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nature Medicine, 18:1224. 63. H. Zhang, X. Chen, J. Wang, W. Guang, W. Han, H. Zhang, X. Tan, and Y. Gu. (2014). EGR1 decreases the malignancy of human non-small cell lung carcinoma by regulating KRT18 expression. Sci. Rep., 4:5416. 64. A. Sadanandam, E. G. Rosenbaugh, S. Singh, M. Varney, and R. K. Singh. (2010). Semaphorin 5A promotes angiogenesis by increasing endothelial cell proliferation, migration, and decreasing apoptosis. Microvasc Res, 79:1. 65. A. Sadanandam, M. L. Varney, S. Singh, A. E. Ashour, N. Moniaux, S. Deb, S. M. Lele, S. K. Batra, and R. K. Singh. (2010). High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis. Int J Cancer, 127:1373. 66. L. Shen, Q. Shi, and W. Wang. (2018). Double agents: genes with both oncogenic and tumor-suppressor functions. Oncogenesis, 7:25. 67. A. S. Aranko, J. S. Oeemig, T. Kajander, and H. Iwaï. (2013). Intermolecular domain swapping induces intein-mediated protein alternative splicing. Nat Chem Biol, 9:616. 68. F. Zunke, and S. Rose-John. (2017). The shedding protease ADAM17: Physiology and pathophysiology. Biochim Biophys Acta Mol Cell Res, 1864:2059. 69. A. Sadanandam, M. L. Varney, and R. K. Singh. (2008). Identification of Semaphorin 5A Interacting Protein by Applying Apriori Knowledge and Peptide Complementarity Related to Protein Evolution and Structure. Genom Proteom Bioinf, 6:163. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69694 | - |
dc.description.abstract | Semaphorin 5A (SEMA5A)是semaphorin家族的一員,被視為是參與神經軸突發展的重要分子。在先前的研究中我們發現SEMA5A 可以做為非吸菸肺癌女性病患的生物性標誌物,並且在肺癌細胞中有抑制癌細胞生長及轉移的功能。然而,SEMA5A所參與的調控機制目前仍尚未明朗,因此本篇研究的目的便是探討SEMA5A不同的蛋白區域在抑制肺癌細胞的功能中所扮演的角色。首先,我們在大量表現SEMA5A以及SEMA5A細膜外區域的組別中,觀察到對於肺癌細胞A549及H1299都有顯著的抑制生長及轉移的效果。接著,我們以基因微陣列分析來檢驗大量表現不同SEMA5A蛋白區域後,肺癌細胞A549的基因表現情況。根據分析的結果,我們發現在干擾素(interferon)訊息傳遞途徑中的基因,例如STAT1, STAT2, IRF9, G1P2 以及 IFIT1,在大量表現SEMA5A以及SEMA5A細膜外區域的組別中有顯著上升的情況。另外,於先前的研究中發現,分泌型的SEMA5A細膜外區域與腫瘤的發生有關,然而在抑制脫落酶ADAM17使SEMA5A膜外區域的釋出減少後,並沒有減弱抑癌的效果,所以我們推論另有未發現的蛋白參與SEMA5A的抑癌機制。因此,我們想藉由質譜儀分析來找出與SEMA5A有交互作用的蛋白。然而目前只有在共同免疫沉澱法以及質譜儀分析中找到正控制的SEMA5A,後續仍然需要更多的研究來探討抑癌機制中會與SEMA5A有交互作用的蛋白。總結,在本篇研究中,我們發現SEMA5A膜外區域會透過增加干擾素傳遞途徑中的抑癌基因,來造成抑制肺癌細胞的效果。 | zh_TW |
dc.description.abstract | Semaphorin 5A (SEMA5A) is one member of semaphorin family, which was identified as an axon guidance molecule in nervous systems. In our previous studies, SEMA5A was identified as a prognostic biomarker for lung cancer in nonsmoking women and acted as a tumor suppressor gene in inhibiting the proliferation and migration of lung cancer cells. Yet, the regulatory mechanism of SEMA5A was not clear. Therefore, the purpose of this study was to explore the roles of different domains of SEMA5A on the tumor suppressive effects in lung cancer cell lines. First, we found the overexpression of 5A-Full and 5A-ECD significantly inhibited the proliferation and migration in both A549 and H1299 cells. Next, microarray analyses were performed in lung cancer A549 cells expressing different domains. The results showed the expression levels of genes involved in interferon signaling pathway, such as STAT1, STAT2, IRF9, G1P2 and IFIT1, were significantly increased in overexpressing SEMA5A full length (5A-Full) and SEMA5A extracellular domain (5A-ECD) groups. The secreted form of SEMA5A was reported to be involved in tumor progression. However, tumor-suppressing effects were still observed in cells silencing the sheddase ADAM17 to decrease cleaving the extracellular domain of SEMA5A, suggesting the presence of unidentified proteins involved in the tumor suppressive effects. Therefore, mass spectrometry was used to identify the proteins interacting with SEMA5A. Currently, only the positive control SEMA5A was identified in co-immunoprecipitation and mass spectrometry assays. More experiments are still needed to explore the proteins interacting with SEMA5A and involved in the tumor-suppressing pathways. In summary, this study identified that the of extracellular domain of SEMA5A could upregulate genes in interferon signaling pathways and result in the suppressive effects of lung cancer cells. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T03:24:07Z (GMT). No. of bitstreams: 1 U0001-1808202003230900.pdf: 6044090 bytes, checksum: 6bc4eef82adbffbf9c439b0dfdf6051f (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 目錄 致謝 I 摘要 II Abstract IV List of Tables VIII List of Figures IX Chapter 1 Introduction 1 1.1 Non-small-cell lung cancer 1 1.2 Semaphorin family in cancer 2 1.3 The relationship between SEMA5A and lung adenocarcinoma 3 1.4 The aim of study 4 Chapter 2 Materials and Methods 6 2.1 Cell culture and treatments 6 2.2 Plasmid construction 6 2.3 Transfection and RNA interference 7 2.4 RNA extraction, reverse transcription and quantitative RT-PCR analysis 8 2.5 Protein extraction 8 2.6 Western blotting analysis 9 2.7 Cell proliferation assay 9 2.8 Wound healing assay 10 2.9 Cell colony formation assay 10 2.10 Flow cytometry analysis of cell cycle and cell apoptosis 11 2.11 Co-immunoprecipitation assay 11 2.12 Silver staining 12 2.13 Mass spectrometer 12 2.14 Illumina microarray analysis 13 2.15 Statistical analysis 14 Chapter 3 Results 15 3.1 Examined the functional roles of different SEMA5A domains in lung adenocarcinoma 15 3.2 Expression profilings of A549 cells overexpressing different SEMA5A domains 16 3.3 Overexpressing SEMA5A and SEMA5A-ECD in protein level 21 3.4 Silence ADAM17 to validate the rescued tumor-suppressing functional abilities of SEMA5A and SEMA5A-ECD 22 3.5 Investigation of the proteins interacting with SEMA5A and involved in tumor-suppress pathways 23 Chapter 4 Discussion 25 4.1 The differentially expressed genes in A549 cells regulated by different SEMA5A domains 26 4.2 SEMA5A extracellular domain inhibited cell proliferation and migration 28 4.3 Silence of ADAM17 did not rescued the tumor-suppressing effects 30 4.4 Summary 31 Tables 33 Figures 38 References 55 | |
dc.language.iso | en | |
dc.title | 探討Semaphorin 5A細胞膜外區域在非小細胞肺癌中抑制腫瘤的角色 | zh_TW |
dc.title | Identification of the Tumor-Suppressing Roles of Semaphorin 5A Extracellular Domain in Non-Small-Cell Lung Cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蔡孟勳(Mong-Hsun Tsai),周綠蘋(Lu-Ping Chow),佘玉萍(Yuh-Pyng Sher) | |
dc.subject.keyword | 肺癌,Semaphorin5A,膜外區域,抑癌, | zh_TW |
dc.subject.keyword | Lung Cancer,Semaphorin5A,Extracellular Domain,Tumor suppressor, | en |
dc.relation.page | 60 | |
dc.identifier.doi | 10.6342/NTU202003914 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-08-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生理學研究所 | zh_TW |
顯示於系所單位: | 生理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1808202003230900.pdf 目前未授權公開取用 | 5.9 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。